Aclaris Therapeutics, Inc. · NASDAQ:ACRS
Aclaris Therapeutics — Merger or Acquisition (August 2017)
16 slides from Aclaris Therapeutics's merger presentation, Aug 8, 2017
Slide 1: Confluence Life Sciences Acquisition
© Copyright 2017 Aclaris Therapeutics. All rights reserved. A-1 Dr. Neal Walker President and CEO August 2017 CONFLUENCE LIFE SCIENCES ACQUISITION
Slide 2: Disclaimer
Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan," "pote
Slide 3: Confluence Life Science Acquisition Summary
Confluence Life Science Acquisition Summary Co-inventors of tofacitinib and former leaders of Pfizer kinase program (including JAK inhibitors) Kinome experts - chemists and biologists; combined 300+ years of drug discovery experience Significant experience in small molecule drug discovery through Ph
Slide 4: Transaction Founded on a Strategic Partnership
Transaction Founded on a Strategic Partnership Fully Integrated Biopharmaceutical Company and Leading Developer of Small Molecule Therapeutics for Immunological Disorders of the Skin and other Organs Pre-transaction Aclaris Oral and topical assets Robust intellectual property estate Drug development
Slide 5: Financial Highlights
Financial Highlights Confluence equityholders received an upfront payment of $10 million in cash and $10 million in common stock Up to $80 million in contingent payments upon achievement of certain development, regulatory and commercial milestones, plus additional low-single digit royalties Deal Ter
Slide 6: Acquisition of Confluence Expected to Drive Future Growth
Acquisition of Confluence Expected to Drive Future Growth Short term and Long term Supports and extends Aclaris’ JAK kinase inhibitor programs Enables targeted development of novel therapeutics for inflammation and immunology in dermatology and adjacent therapeutic areas Synergies in drug discovery
Slide 7: Confluence Assets
Confluence Assets ITK Inhibitors “Oral Anti-IL17” Psoriasis, Atopic Dermatitis Oral and soft topical Highly selective, covalent and non-covalent Oral and soft topical JAK Inhibitors Psoriasis / Psoriatic Arthritis, RA, Chronic Inflammation Highly potent and designed to escape the tachyphylaxis assoc
Slide 8: Platform - KINect Innovation Engine
Platform - KINect™ Innovation Engine Type 1 active conformation 215 cysteine kinases Type 2 DFG out conformation 128 cysteine kinases Type 1.5 C-helix out conformation 68 cysteine kinases Concentrated effort in immunology: autoimmune disease and chronic inflammation Cysteinome targeted chemical libr
Slide 9: Platform - Research and Development Capabilities
Platform - Research and Development Capabilities Biomarker Assay Development Clinical Biomarker Assessment In vivo Efficacy and PK Studies PK/PD Relationship Release Assay Validation TRANSLATIONAL RESEARCH COMPUTATIONAL & MEDICINAL CHEMISTRY Leaders in Mechanistic Enzymology Custom Assay Development
Slide 10: Confluence People - Ex-Pfizer Kinase and JAK experts
Confluence People - Ex-Pfizer “Kinase and JAK experts” Former Executive Director, Pfizer Inflammation Research and Leader of Global Kinase Technology Team >95 publications and patents (>30 total on kinases) Joseph Monahan, PhD CSO/Founder Former VP Research & Global Head, Pfizer Inflammation, co-lea
Slide 11: The Kinase Opportunity – Rational Targeted Drug Discovery
The Kinase Opportunity – Rational Targeted Drug Discovery Creating New Medicines Targeting Previously Inaccessible Parts of the Kinome Kinase Drugs Represented $240B in Aggregate Global Sales from 2011-2015 Proprietary chemical library and integrated capabilities for interrogating the Kinome Solves
Slide 12: Confluence Pipeline
Confluence Pipeline MK2: Innate immune response – clinically validated by Humira®, Actemra®, Kineret® ITK: T-cell receptor dependent autoimmune disease – clinically validated by Neoral®, Prograf®, Orencia® JAK: Inflammatory cytokine dependent inflammation – clinically validated by Xeljanz®, Jakifi®
Slide 13: Confluence Pipeline: Signaling Inhibitors for Dermatology
Confluence Pipeline: Antigen and Cytokine Receptor Signaling Inhibitors for Dermatology Alopecia Areata: IFNg (JAK1/2) and IL-15 (JAK1/3) Vitiligo: IFNg (JAK1/2) and IL-15 (JAK1/3) Psoriasis: IFNg (JAK1/2), IL-12/23 (JAK2/Tyk2), IL-22 (JAK1/Tyk2) and IL-21 (JAK1/3) Atopic Dermatitis: IFNg (JAK1/2),
Slide 14: Benefits of Targeted, Topical Soft Drugs
Benefits of Targeted, Topical Soft Drugs Improved understanding of cytokine pathways in skin enables targeted pharmacology Differential formulations allow skin penetration to depth of disease activity Topical soft drugs are designed to be: Active in the skin But, inactivated in the bloodstream
Slide 15: Confluence Adds Complementary Pipeline
Program Indication(s) Discovery Pre-Clinical Clinical Phase 1 Phase 2 Phase 3 Filed A-101 (40%) Topical Seborrheic Keratosis A-101 (45%) Topical Common Warts ATI-50001 Oral Alopecia Areata ATI-50002 Topical Alopecia Areata ATI-50001, ATI-50002 Oral, Topical Vitiligo “Soft” JAK Inhibitor Topical Hair
Slide 16: Building a Fully Integrated Biopharmaceutical Company
Building a Fully Integrated Biopharmaceutical Company Commitment to Patients Focus on “white-space” or underserved diseases where treatment gaps exist Research and Development Scientific leadership in JAK and kinase inhibitor chemistry - innovative clinical and regulatory strategies Innovative and d
Aclaris Therapeutics — Merger or Acquisition (August 2017) on 6ix